Oncolytic Viruses as an Emerging Aspect of Immune Oncology
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: 31 August 2024 | Viewed by 1341
Special Issue Editor
Special Issue Information
Dear Colleagues,
Oncolytic viruses (OVs), mainly known for their ability to specifically target and cause the lysis of cancer cells, have more recently become accepted as a unique and promising aspect of immuno-oncology. Through the process of virus replication and innate responses to the infection process in tumors, the tumor microenvironment (TME) often undergoes a reprogramming and a conversion of immune suppression into immune stimulation, which can lead to potent systemic immune responses directed against distant tumor cells throughout the body. Furthermore, by heating up the TME, solid cancers can be sensitized to other forms of immunotherapy (i.e., immune checkpoint inhibitors, adoptive cell therapies, tumor vaccines, etc.) through OV treatment. Due to their multimechanistic modes of action, OVs represent an exciting approach in immuno-oncology, which can be applied either in a monotherapy setting or as components of rationally designed combination approaches for potential synergistic effects.
The Special Issue aims to highlight this exciting translational approach in immuno-oncology. We are pleased to invite you to submit original contributions related to this topic, including reports on novel OV vectors with immuno-stimulatory potential, OV-based tumor vaccines, combination immunotherapy approaches, and clinical studies involving OV-based immunotherapeutics in cancer patients.
We invite investigators to submit original research articles, as well as review articles, that will stimulate the scientific community and enhance the growing body of knowledge on oncolytic viruses and cancer immunotherapy. I/We look forward to receiving your contributions.
Dr. Jennifer Altomonte
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- oncolytic virus
- virotherapy
- immunotherapy
- immuno-oncology
- tumor vaccine
